280 related articles for article (PubMed ID: 20585746)
21. Biologics for psoriasis: What is new?
Özyurt K; Ertaş R; Atasoy M
Dermatol Ther; 2019 May; 32(3):e12916. PubMed ID: 30972872
[TBL] [Abstract][Full Text] [Related]
22. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
23. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
[TBL] [Abstract][Full Text] [Related]
24. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis.
Stiff KM; Glines KR; Porter CL; Cline A; Feldman SR
Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1209-1218. PubMed ID: 30449211
[TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
Gottlieb AB
Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
[No Abstract] [Full Text] [Related]
26. Depression? It's the Disease NOT the Drug.
Kircik LH
J Drugs Dermatol; 2018 Aug; 17(8):s28. PubMed ID: 30124736
[TBL] [Abstract][Full Text] [Related]
27. Biologic agents in the treatment of psoriasis.
Guarneri F; Guarneri C; Guarneri B
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):193-217. PubMed ID: 19075983
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
29. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
[TBL] [Abstract][Full Text] [Related]
30. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
[TBL] [Abstract][Full Text] [Related]
31. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
32. Update on TNF Inhibitors.
Kerdel FA
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S67-70. PubMed ID: 27526035
[TBL] [Abstract][Full Text] [Related]
33. Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
[TBL] [Abstract][Full Text] [Related]
34. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
Gaspari AA; Tyring S
Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
[TBL] [Abstract][Full Text] [Related]
35. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
36. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Menter A; Gottlieb A; Feldman SR; Van Voorhees AS; Leonardi CL; Gordon KB; Lebwohl M; Koo JY; Elmets CA; Korman NJ; Beutner KR; Bhushan R
J Am Acad Dermatol; 2008 May; 58(5):826-50. PubMed ID: 18423260
[TBL] [Abstract][Full Text] [Related]
37. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
38. Japanese guidance for use of biologics for psoriasis (the 2019 version).
Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
[TBL] [Abstract][Full Text] [Related]
39. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M
Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
[No Abstract] [Full Text] [Related]
40. Combination therapy of biologics with traditional agents in psoriasis.
Guenther LC
Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
